The startup develops gene therapies utilizing human synthetic chromosome technology (hSynC) to engineer anti-tumoral T-cells for cancer immunotherapy. This approach aims to enhance treatment efficacy in oncology and extend applications to other areas with significant medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene therapy approaches for cancer immunotherapy and genetic diseases face challenges in efficient and safe gene delivery and expression, limiting their therapeutic potential. Traditional methods often rely on viral vectors, which can trigger immune responses and have limited cargo capacity, or non-viral methods with low transfection efficiency.
Solution
CG Bioengineering is developing a novel gene delivery and expression platform based on human synthetic chromosome (hSynC) technology to overcome the limitations of existing gene therapy methods. The hSynC platform allows for the delivery of large genetic payloads without the use of viral vectors, reducing the risk of immunogenicity and insertional mutagenesis. This non-viral approach enables the creation of both _in vivo_ and _ex vivo_ therapeutics for a range of diseases, including cancers, genetic disorders, and autoimmune conditions. By engineering anti-tumoral T-cells with hSynC, the company aims to enhance treatment efficacy in oncology and extend the application of gene-based medicines to areas with unmet medical needs.
Target Audience
The primary target audience includes researchers and clinicians in oncology, gene therapy, and regenerative medicine seeking improved gene delivery solutions for therapeutic development.
Features
- Non-viral gene delivery system based on human synthetic chromosomes (hSynC)
- Large cargo capacity for delivering complex genetic payloads
- Reduced risk of immunogenicity and insertional mutagenesis compared to viral vectors
- Potential for both _in vivo_ and _ex vivo_ therapeutic applications
- Ability to engineer anti-tumoral T-cells for cancer immunotherapy
- Platform applicable to genetic diseases and autoimmune disorders